Is Compounded Tirzepatide the Same as Mounjaro or Zepbound?

Same active molecule — different product and different regulatory standing. FDA approval applies to specific finished products, not to a molecule in general. Eli Lilly’s tirzepatide products — Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea — are FDA-approved finished drugs with manufacturer-level FDA inspection, batch-tested potency and sterility, standardized labeling, and post-market surveillance. Compounded tirzepatide uses the same active molecule but is a pharmacy preparation, not an approved product, so it does not carry the same standing even though the molecule is identical.

The useful question is always which exact product, not just the ingredient name. A compounded preparation from a licensed 503A or 503B pharmacy that performs third-party potency testing is a regulated medical product; an unverified vial labeled “research use only” is not. See our GLP-1 medication comparison for a full side-by-side of approved and investigational incretin agents, and our which peptides are FDA-approved reference for the broader principle.

Both contain the same active molecule (tirzepatide) and work through the same GIP/GLP-1 mechanism. The differences are regulatory, not molecular.

Shortage status changes over time and directly affects whether compounding a copy of an FDA-approved tirzepatide product is permitted — verify at the time of care.

Compounded tirzepatide exists largely for access. During periods when the FDA lists an FDA-approved tirzepatide product as in shortage, demand can outstrip supply, and brand-name medication can be expensive or hard to fill through insurance. Compounding pharmacies — operating under federal rules that permit compounded copies during a declared shortage — provide a pharmacy-prepared alternative. Compounded preparations are also used when a patient needs a specific formulation a standard product cannot provide (for example, an allergen-free or non-standard-dose version), determined by a prescriber.

The trade-off is regulatory: a compounded version fills an access gap but does not carry the FDA’s manufacturer-level approval of that specific finished product. That is why the sourcing pharmacy and its testing practices — not the molecule — are what make a compounded preparation safe or unsafe. Our FDA compounding status tracker tracks the current shortage picture, and our 503A vs 503B compounding pharmacy guide explains how the two pharmacy types differ.

Safety depends almost entirely on sourcing. Legitimate compounded tirzepatide is dispensed by a licensed 503A or 503B pharmacy after a physician evaluation, with third-party purity and potency testing, and is a regulated medical preparation. The danger is the unregulated market — “research use only” vials and unverified powders that are not made or tested for human use. The FDA has issued statements describing concerns with unapproved GLP-1 drugs and adverse events linked to compounded and counterfeit products from unregulated sources.

We are a physician practice, not a medication retailer. Our default is the FDA-approved product — Mounjaro or Zepbound — whenever it is clinically appropriate and available, because it carries manufacturer-level FDA oversight. We use a compounded preparation only when it is clinically appropriate and the approved product is unavailable or not the right fit, sourced exclusively from a named, licensed U.S. 503A or 503B pharmacy with third-party potency and sterility testing.

Compounding a drug that copies an FDA-approved product is generally restricted under federal law, with an important exception during periods when the FDA lists the drug as in shortage. Because shortage status and the resulting compounding eligibility shift over time, this is exactly the kind of fact to verify at the time of care rather than assume from any web page. Our FDA compounding status tracker and our 503A vs 503B compounding pharmacy guide explain why these distinctions matter and how licensed pharmacies differ.

Patients across the Las Vegas valley — including Henderson, Summerlin, Green Valley, and North Las Vegas — are seen at LiveNow Longevity, in person at our southeast clinic at Eastern Avenue and the 215 or by secure telehealth anywhere in Nevada. After an evaluation with Dr. Kamen, you get an honest comparison of FDA-approved and — where appropriate — compounded tirzepatide, including how each is sourced and what each actually costs. For the broader picture of physician-supervised options, see our pages on tirzepatide in Las Vegas, semaglutide in Las Vegas, and medical weight loss in Las Vegas.